Pharvaris N.V.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Berndt Axel Edvard Modig
- Full Time Employees
- 108
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- J.H. Oortweg 21 Leiden Netherlands 2333 CH
- IPO Date
- Feb 5, 2021
- CIK
- 0001830487
- Website
- pharvaris.com
- Similar Companies
- Business
- Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment and prevention of bradykinin-mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Founded in 2015 and headquartered in Zug, Switzerland, with operations in the Netherlands and the United States, the company advances deucrictibant as its lead candidate: PHVS416, an immediate-release softgel capsule for on-demand HAE attack treatment; and PHVS719, an extended-release tablet for prophylactic use. Its pipeline targets patients aged 12 and older across global markets, with pivotal Phase 3 trials conducted in 24 countries. In December 2025, Pharvaris announced positive topline results from the RAPIDe-3 Phase 3 trial of deucrictibant immediate-release capsules, meeting the primary endpoint of median time to onset of symptom relief at 1.28 hours versus over 12 hours for placebo, and achieving all 11 secondary endpoints including rapid symptom resolution; topline data from the ongoing CHAPTER-3 prophylactic trial is expected in the second half of 2026, with a U.S. New Drug Application submission planned for the first half of 2026. Earlier in July 2025, the company completed an upsized $175 million underwritten public offering of ordinary shares to fund late-stage clinical programs, U.S. commercialization efforts including sales and marketing team hiring, and general corporate purposes.
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
Tudor Investment Corp ET AL Takes Position in Pharvaris N.V. $PHVS
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages
Pharvaris N.V. $PHVS Shares Purchased by General Atlantic L.P.
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting